BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC

Boehringer Ingelheim Animal Health USA Inc. specializes in the manufacturing and delivery of biological veterinary vaccines, with a focused expertise in oral rabies vaccine (ORV) baits for wildlife disease control. The company produces coated sachet baits containing live attenuated rabies virus strains, designed for targeted distribution to raccoon and other vector species in wild populations. Their technical capabilities encompass formulation science, bait matrix development, cold-chain logistics, and compliance with USDA animal health regulations for biological product manufacturing under NAICS 325414. Key differentiators include proprietary bait delivery systems, validated stability protocols under field conditions, and experience in large-scale, geographically distributed wildlife vaccination campaigns requiring precise deployment per USDA-specified operational spec sheets. The contractor maintains a consistent and deep working relationship with the U.S. Department of Agriculture, primarily supporting the Animal and Plant Health Inspection Service (APHIS) in national wildlife rabies management programs. Their work includes end-to-end delivery of vaccine baits, storage, and disposal services aligned with federal zoonotic disease control protocols. This partnership reflects a trusted vendor status in USDA’s long-term wildlife health initiatives, where reliability, regulatory adherence, and logistical precision are critical. The company’s primary industry focus is biological product manufacturing for veterinary use, specifically non-diagnostic immunobiologics for wildlife conservation and public health protection. This vertical specialization positions them as a critical supplier in the niche market of wildlife disease intervention, serving federal agencies engaged in One Health initiatives. As a 2L entity headquartered in Duluth, Georgia, Boehringer Ingelheim Animal Health USA Inc. operates as a subsidiary of a global animal health leader, leveraging corporate R&D and manufacturing infrastructure. While no specific government certifications are listed, their consistent performance on USDA contracts demonstrates compliance with federal biological product standards and supply chain integrity requirements for sensitive veterinary biologics.